Hansa Biopharma Announces Exclusive Agreement with Sarepta Therapeutics to Develop Imlifidase

Jul 3, 2020PA1432

Sarepta is granted an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD).

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.